References

1. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for inter-individual differences in drug response. Ann Rev Genomics Hum Genet 2001; 2:9-39.

2. Ng PC, Henikoff S. Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002; 12:436-446.

3. Hoogendoorn B, Coleman SL, Guy CA, et al. Functional analysis of human promoter polymorphisms. Hum Mol Genet 2003; 12:2249-2254.

4. Cooper DN. Human Gene Evolution. Oxford: BIOS Scientific, 1999.

5. Hirschhorn JN, Lohmueller K, Byrne E, Hirschhorn K. A comprehensive review of genetic association studies. Genet Med 2002; 4:45-61.

6. Ioannidis JPA, Trikalinos TA, Ntzani EE, et al. Genetic associations in large versus small studies: an empirical assessment. Lancet 2003; 361:567-571.

7. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-alpha gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32:650-654.

8. Fullerton SM, Clark AG, Weiss KM, et al. Apolipoprotein E variation at the sequence hap-lotype level: implications for the origin and maintenance of a major human polymorphism. Am J Hum Genet 2000; 67:881-900.

9. Rigat B, Hubert C, Alhenc-Gelas F. et al. An insertion/deletion polymorphism in the angio-tensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990; 86:1343-1346.

10. Dawson SJ, Wiman B, Hamsten A, et al. The two allele sequences of a common polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene respond differently to interleukin-1 in HepG2 cells. J Biol Chem 1993; 268:10739-10745.

11. Varo N, Iraburu MJ, Varela M, Lopez B, Etayo JC, Diez J. Chronic AT (1) blockade stimulates extracellular collagen type I degradation and reverses myocardial fibrosis in spontaneously hypertensive rats. Hypertension 2000; 35:1197-1202.

12. Jeunemaitre X, Sourbrier F, Kotelevstev YV, et al. Molecular basis of human hypertension: role of angiotensnogen. Cell 1992; 72:169-180.

13. Katsuya T, Koike G, Yee TW, et al. Association of angiotensinogen gene T235 variant with increased coronary heart disease. Lancet 1995; 355:434-442.

14. Winkelmann BR, Russ AP, Nauck M, et al. Angiotensinogen M235T polymorphism is associated with plasma angiotensinogen and cardiovascular disease. Am Heart J 1999; 137:698-705.

15. Ludwig EH, Borecki IB, Ellison RC, et al. Associations between candidate loci angiotensin-converting enzyme and angiotensinogen with coronary heart disease and myocardial infarction: the NHLBI Family Heart Study. Ann Epidemiol 1997; 7:3-12.

16. Tiret L, Ricard S, Poirier O, et al. Genetic variation at the angiotensiogen locus in relation to high blood pressure and myocardial infarction: the ECTM study. J Hypertens 1995; 13:311-317.

17. Sethi AA, Nordestgaard BG, Tybjaerg-Hansen A. Angiotensinogen gene polymorphism, plasma angiotensinogen, and risk of hypertension and ischaemic heart disease: a metaanalysis. Arterioscler Thromb Vasc Biol 2003; 23:1269-1275.

18. Hingorani AD, Jia H, Stevens PA, Hopper R, Dickerson JE, Brown MJ. Renin-angiotensin system gene polymorphisms influence blood pressure and the response to angiotensin converting enzyme inhibition. J Hypertension 1995; 13:1602-1609.

19. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-ezyme inhibitor, ramipril, on cardiovascular events in high risk patients. The Heart Outcomes Prevention Evaluation Study investigators (see comments). New Engl J Med 2000; 342:145-153.

20. Rioux PP. Clinical trials in pharmacogenetics and pharmacogenomics: methods and applications. Am J Health Syst Pharm 2000; 57:887-898.

21. Evans AE, Poirer O, Kee F, Lecerf L, et al. Polymorphisms of the angiotensin-converting-enzyme gene in subjects who die from coronary heart disease. QJM 1994; 87:211-214.

22. Schunkert H, Hense S, Holmer SR, Stender M, Perz S, et al. Association between deletion polymorphism of the angiotensin-converting enzyme gene and left ventricular hypertrophy. New Engl J Med 1994; 330:345-348.

23. Montgomery HE, Should the contribution of ACE gene polymorphism to left ventricular hypertrophy be reconsidered? Heart 1997; 77:489-490.

24. Samani NJ, Thompson JR, O'Toole L, Channer K, Woods KL. A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarctions. Circulation 1996; 94:708-712.

25. Sharma P. Meta-analysis of the ACE gene in ischaemic stroke. J Neurol Neurosurg Psych 1998; 64:227-230.

26. Sayed-Tabatabaei FA, Houwing-Duistermaat JJ, van Duijn CM, Witteman JCM. Angioten-sin-converting enzyme gene polymorphism and carotid artery wall thickness. A meta-analy-sis. Stroke 2003; 34:1634-1639.

27. Safar ME, Lajemi M, Rudnichi A, Asmar R, Benetos A. Angiotensin-converting enzyme D/I gene polymorphism and age-related changes in pulse pressure in subjects with hypertension. Arterioscl Thromb Vasc Biol 2004; 24:1 -5.

28. Zee RYL, Lou Y, Griffiths LR, Morris BJ, et al. Association of a polymorphism of the angio-tensin I converting enzyme gene with essential hypertension. Biochem Biophys Res Commun 1992; 184:9-15.

29. Sasaki M, Oki T, Luchi A, et al. Relationship between the angiotensin converting enzyme gene polymorphism and the effects of enalapril on left ventricular hypertrophy and impaired diastolic filling in essential hypertension: M-mode and pulsed Doppler echocardiography studies. J Hypertens 1996; 14:1403-1408.

30. Dudley C, Keavney B, Casadei B et al. Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of rennin-angiotensin system genes. J Hypertens 1996; 14:259-262.

31. McNamara DM, Holubkov R, Janosko, et al. Pharmacogenetic interactions between beta-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 2001; 103:1644-1648.

32. Paillard F, Chansel D, Brand E, Benetos A, Thomas F, et al. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in normal population. Hypertension 1999; 34:423-429.

33. Pojoga L, Gautier S, Blanc H, Guyene TT, et al. Genetic determination of plasma aldosterone levels in essential hypertension. Am J Hypertens 1998; 11:856-860.

34. Hautanena A, Lankien L, Kupari M, et al. Associations between aldosterone synthase gene polymorphism and adrenocortical function in males. J Int Med 1998; 244:11-18.

35. Kupari M, Hautanen A, Lankinen L, Koskinen P, Virolainen J, et al. Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass and function. Circulation 1998; 97:569-575.

36. Reihauss E, Innis M, Macintyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8:334-339.

Green SA, Turki J, Innis M, Liggett SB. Influence of beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33:9414-9419. Green SA, Turki J, Bejarno P, Hall IP, Liggett SB. Influence of ß2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13:25-33.

Turki J, Lorenz JN, Green SA, Donnelly ET, et al. Myocardial signalling defects and impaired cardiac function of a human beta 2-adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 1996; 93:10483-10488.

Skrabal F, Kotano P, Luft FC. Mini review: inverse regulation of a-2 and ß-2 adrenergic receptors in salt sensitive hypertension: an hypothesis. Life Sci 1989; 45:2061-2076. Cockcroft JR, Gazis AG, Cross DJ, Wheatley A, et al. ß-2 adrenoceptor polymorphism determines vascular reactivity in humans. Hypertension 2000; 36:371-375. Hoit BD, Suresh DP, Craft L, Walsh RA, Liggett SB. ß2-adrenergic receptor polymorphisms at amino acid 16 differentially influence agonist-stimulated blood pressure and peripheral blood flow in normal individuals. Am Heart J 2000; 139:537-542.

Svetkey LP, Chen Y-T, McKeown S-P, Preis L, et al. Preliminary evidence of linkage of salt sensitivity in black Americans at the ß-2 adrenoceptor locus. Hypertension 1997; 29:918-922.

Bray MS, Kruskall J, Li L, Ferrell R, Kardia S, et al. Positional genomic analysis identifies ß2-adrenergic receptor gene as a susceptibility locus for human hypertension. Circulation 2000; 101:2877-2882.

Jia H, Sharma P, Hopper R Dickerson C, et al. ß2-Adrenoceptor gene polymorphisms and blood pressure in East Anglian Caucasians. J Hypertens 2000; 18:687-693. Liggett SB, Wagoner LE, Craft LL, Hornung RW, et al. The Ile164 ß2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 1998; 102:1534-1539.

Wagoner LE, Craft LL, Singh LL, Suresh DP, Zengel PW, et al. Polymorphisms of the the ß2-adrenergic receptor determine exercise capacity in patients with heart failure. Circ Res 2000; 86:834-840.

Gratze G, Fortin J, Labugger R, Binder A, Kotano P, et al. ß2-Adrenergic receptor variants affect resting blood pressure and agonist-induced vasodilation in young adult Caucasians. Hypertension 1999; 33:1425-1430.

Perregaux D, Chaudhuri A, Rao S, Airen A, et al. Brachial vascular reactivity in blacks. Hypertension 2000; 36:866-871.

Brodde OE, Buscher R, Tellkamp R, Radke J, Dhein S, Insel PA. Blunted cardiac responses to receptor activation in subjects with Thr164Ile beta(2)-adrenoceptors. Circulation 2001; 103:1048-1050.

Wang Y, Marsden PA. Nitric oxide synthases: biochemical and molecular regulation. Curr Opin Nephrol Hypertens 1995; 4:12-22.

Moncada S, Higgs A. The L-Arginine nitric oxide pathway. New Engl J Med 1993; 329:2002-2012.

Haynes WG, Noon JP, Walker BR, Webb DJ. L-NMMA increases blood pressure in man. Lancet 1993; 342:931-932.

Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 1998; 32: 3-8.

Hingorani A, Liang CF, Fatibene J, Lyon A, et al. A common variant of the endothelial nitric oxide synthase (Glu298 ! Asp) is a major risk factor for coronary artery disease in the UK. Circulation 1999; 100:1515-1520.

Hibi K, Ishigami T, Tamura K, Mizushima S, et al. Endothelial nitric oxide synthase gene polymorphism and acute myocardial infarction. Hypertension 1998; 32:521-526. Shimasaki Y, Yasue H, Yoshimura M, Nakayama M, et al. Association of the missense mutation Glu298Asp variant of the endothelial nitric oxide synthase gene with myocardial infarction. J Am Coll Cardiol 1998; 31:1506-1510.

58. Yoshimura M,Yasue H, Nayakama M, Shimsaki Y, et al. A missense Glu298Asp variant in the endothelial nitric oxide synthase gene is associated with coronary spasm in the Japanese. Hum Genet 1998; 103:65-69.

59. Lacolley P, Gautier S, Poirier O, Pannier B, et al. Nitric oxide synthase gene polymorphisms, blood pressure and aortic stiffness in normotensive and hypertensive subjects. J Hypertens 1998; 16:31-35.

60. Avolio AP, Deng FQ, Li WQ, Luo YF, et al. Effects of aging on arterial distensibility in populations with high and low prevalence of hypertension: Comparision between urban and rural communities in China. Circulation 1985; 71:202-210.

61. Li DY, Brooke B, Davis EC, Mecham RP, et al. Elastin is an essential determinant of arterial morphogenesis. Nature 1998; 393:276-280.

62. Li DY, Faury G, Taylor DG, Boyle WA, et al. Novel arterial pathology in mice and humans hemizygous for elastin. J Clin Invest 1998; 102:1783-1787.

63. Ewart AK, Morris AC, Atkinson D, Weishan J, et al. Hemizygosity at the elastin locus in a developmental disorder. Nat Genet 1993; 5:11-15.

64. Tassabehji M, Metcalfe K, Donnai D, Hurst J, et al. Elastin: genomic structure and point mutations in patients with supravalvular aortic stenosis. Hum Mol Genet 1997; 6:1029-1036.

65. Ewart AK, Morris CA, Ensing GJ, Loker J, et al. Human vascular disorder, supravalvular aortic stenosis, maps to chromosome 7. Proc Natl Acad Sci USA1993; 90: 3226-3230.

66. Tromp G, Christiano A, Goldstein N, Indik Z, et al. A to G polymorphism in the ELN gene. Nucleic Acids Res 1991; 19:4314.

67. Raybouldd MC, Birley AJ, Hulten M. A Bgl I polymorphism in the human elastin gene (ELN). Clin Genet 1994; 46:212-213.

68. Hanon O, Luong V, Mourard JJ, Bortolotto LA, Jeunemaitre X, Girerd X. Aging, carotid artery distensibility, and the Ser422Gly elastin gene polymorphisms in humans. Hypertension 2001; 38:1185-1189.

69. Wossner JF. Matrix metalloproteinases and their inhibitors in connective tissue remodelling. FASEB 1991; 5:2145-2154.

70. Henney AM, Ye S, Zhang B, Jormsjo S, Whatling C, Eriksson P, Hamsten A. Genetic diversity in the matrix metalloproteinase family. Effects on function and disease progression. Ann NY Acad Sci 2000; 902:27-37.

71. Thompson RW, Holmes DR, Mertens RA, Liao S, Botney MD, Mencham RP, Welgus HG, Parks WC. Production and localization of 92-kilodalton gelatinase in abdominal aortic aneurysms. An elastolytic metalloproteinase expressed by aneurysm-infiltrating macrophages. J Clin Invest 1995; 96:318-326.

72. Zhang B, Ye S, Herrmann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999; 99:1788-1794.

73. Blankenberg S, Rupprecht HJ, Poirier O, Bickel C, Smieja M, Haffner G, Meyer J, Cambien F, Tiret L, for the AtheroGene investigators. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation 2003; 107:1579-1585.

74. Montaner J, Molina CA, Monasterio J, Abilleira S, Arenillas JF, Ribo M, Quintana M, Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003; 107: 598-603.

75. Galis SZ, Khatri JJ. Matrix metalloproteinases in vascular remodelling and atherogenesis. The good, the bad, and the ugly. Cir Res 2002; 90:251-262.

76. Zervoudaki A, Economou E, Stefanadis C, Pitsqvos C, Tsioufis K, Aggeli C, et al. Plasma levels of extracellular matrix metalloproteinases 2 and 9 in patients with essential hypertension before and after antihypertensive treatment. J Hum Hypertens 2003; 17:119-124.

77. Li-Saw-Hee FL, Edmunds E, Blann AD, Beevers DG, Lip GH. Matrix metalloproteinase-9 tissue inhibitor mettaloproteinase-1 levels in essential hypertension. Relationship to left ventricular mass and anti-hypertensive therapy. Int J Cardiol 2000; 75:43-47.

Laviades C, Varo N, Fernandez J, Mayor G, Gil MJ, Monreal I, Diez J. Abnormalities of the extracellular degradation of collagen type I in essential hypertension. Circulation 1998; 98:535-540.

Terashima M, Akita H, Kanazawa K, Inoue N, et al. Stromelysin promoter 5A/6A polymorphism is associated with acute myocardial infarction. Circulation 1999; 99: 2717-2719.

Yoon S, Tromp G, Vongpunsawad S, Ronkainen A, et al. Genetic analysis of MMP3, MMP9 and PAI-1 in Finnish patients with abdominal aortic or intracranial aneurysms. Biochem Biophys Res Commun 1999; 265:563-568.

Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, et al. Stromelysin-1 and inter-

leukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 2000; 20:2657-2662.

Gnasso A, Motti C, Irace C, Carallo C, Liberatoscioli L, Bernardini S, Massoud R, Mattioli

PL, Federici G, Cortese C. Genetic variation in human stromelysin gene promoter and common carotid geometry in healthy male subjects. Arteriosclers Thromb Vasc Biol 2000;

20:1600-1605.

Ghilardi G, Biondi MA, DeMonti M, Turri O, et al. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with carotid artery stenosis. Stroke 2002; 33:2408-2412.

Ye S, Watts GF, Mandalia S, Humphries SE, Henney AM. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 1995; 73:209-215.

Medley TL, Kingwell B, Gatza CD, Pillay P, Cole TJ. Matrix metalloproteinase-3 genotype contributes to age-related aortic stiffening through modulation of gene and protein expression. Circ Res 2003; 92:1-8.

Dart AM, Kingwell BA. Pulse pressure—a review of mechanisms and clinical relevance. J Am Coll Cardiol. 2001; 37:975-984.

de Maat MP, Jukema JW, Ye S, et al. Effect of stromelysin-1 promoter on efficacy of pravastatin in coronary atherosclerosis and restonosis. Am J Cardiol 1999; 83:852-856. Humphries SE, Luong LA, Talmud PJ, et al. The 5A/6A polymorphism in the promoter of the stromelysin-1 (MMP3) gene predicts progression of angiographically determined coronary artery disease in men in the LOCAT gemfibrozil study. Lipid coronary angiography trial. Atherosclersosis 1998; 139:49-56.

Nagashima H, Aoka Y Sakomura Y, Sakuta A, Aomi S, Ishizuka N, Hagiwara N, Kawana M, Kasanuki H. A 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, cerivastatin, suppress production of matrix metalloproteinase-9 in human abdominal aortic aneurysm wall. J Vasc Surg 2002; 36:158-163.

Laufs U, La Fatta V, Plutzky J, Liao JK. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 1998; 97:1129-1135.

Kitakaze M, Karasawa A, Kobayashi H, Tanaka H, Kuzuya T, Hori M. Benidipine: a new Ca2+ channel blocker with a cardioprotective effect. Cardiovas Drug Review 1999; 17:1-15. Hirono O, Fatema K, Nitobe J, Takeishi Y, Kaneko K, Shiga R, Kubota I. Long term effects of benidipine hydrochloride on severe left ventricular hypertrophy and collagen metabolism in patients with essential hypertension. J Cardiol 2002; 39:195-204.

Tan FK, Wang N, Kuwana M, et al. Association of fibrillin-1 single nucleotide polymorphism haplotypes with systemic sclerosis in Choctaw and Japanese populations. Arthritis Rheumatism 2001; 44:893-901.

Powell J, Turner R, Henney A, et al. An association between arterial pulse pressure and variation in the fibrillin-1 gene. Heart 1997; 78:396-398.

Medley TL, Cole TJ, Gatza CD, Wang WYS, Dart AM, Kingwell BA. Fibrillin-1 genotype is associated with aortic stiffness and disease severity in patients with coronary artery disease. Circulation 2002; 105:810-815.

Corbo RM, Scacchi R. Apoliporotein E (APOE) allele distribution in the world. Is APOE*4 a 'thrifty' allele? Ann Hum Genet 1999; 63:310-310.

97. Boerwinkle E, Ellsworth DL, Hallman DM, Biddinger A. Genetic analysis of atherosclerosis: a research paradigm for the common chronic diseases. Hum Mol Genet 1996; 5:1405-1410.

98. Winkelmann BR, Hager J. Genetic variation in coronary heart disease and myocardial infarction: methodological overview and clinical evidence. Pharmacogenomics 2000; 1: 73-94.

99. Wilson PW, Myers RH, Larson MG, Ordovas JM, et al. Apolipoprotein E alleles, dyslipide-mia, and coronary heart disease: the Framingham offspring study. J Am Med Assoc 1994; 272:1666-1671.

100. Gerdes LU, Gerdes C, Kervinen K, et al. The apolipoprotein epsilon4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction: a substudy of the Scandinavian simvastatin survival study. Circulation 2000; 101:1366-1371.

101. Korhonen T, Hannuksela ML, Seppanen S, Kervinen K, Kesaniemi YA, Savolainen MJ. The effect of the apolipoprotein E phenotype on cholesteryl ester transfer protein activity, plasma lipids and apolipoprotein AI levels in hypercholesterolaemic patients on colestipol and lovas-tatin treatment. Eur J Clin Pharmacol 1999; 54:903-910.

102. Sanllehy C, Casals E, Rodriuez-Villar C, et al. Lack of interaction of apolipoprotein E phenotype with the lipoprotein response to lovastatin or gemfibrozil in patients with primary hypercholesterolaemia. Metabolism 1998; 47:560-565.

103. Yamada M. Influence of apolipoprotein E polymorphism on bezafibrate treatment response in dyslipidemic patients. J Atheroscler Thromb 1997; 4:40-44.

104. Yamashita S, Maruyama T, Hirano KL, et al. Molecular biology and pathophysiological aspects of plasma cholesteryl ester transfer protein. Biochem Biophys Acta 2000; 1529:257-275.

105. Kuivenhoven JA, Jukema JW, Zwindermann AH, et al. The role of common variant of the cholesteryl ester transfer protein gene in the progression of coronary atherosclerosis. New Engl J Med 1998; 338:86-93.

106. Ordovas JM, Cupples LA, Corella D, et al. Association of cholesteryl ester transfer protein-TaqlB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk: the Framingham study. Arterioscler Thromb Vasc Biol 2000; 20:1323-1329.

107. Agellon LB, Quinet EM, Gillette TG, et al. Organisation of the human CETP gene. Biochemistry 1990; 29:1372-1376.

108. Agerholm-Larsen B, Nordesgaard BG, Steffensen R, et al. Elevated high density lipoprotein cholesterol is a risk factor for ischaemic heart disease in white women when caused by a mutation in the CETP gene. Circulation 2000; 101:1907-1912.

109. Agerholm-Larsen B, Tybjaerg-Hansen A, Schnohr P, et al. Common CETP mutations, decreased high density lipoprotein cholesterol and possible decreased risk of ischaemic heart disease. The Copenhagen City Heart study. Circulation 2000; 102:2197-2203.

110. Dullaart KP, Hoogenberg K, Riemenes SS, et al. CETP gene polymorphism is a determinant of HDL cholesterol and of the lipoprotein response to a lipid lowering diet in type 1 diabetes. Diabetes 1997; 46:2082-2087.

111. Wallace AJ, Humphries SE, Fisher RM, et al. Genetic factors associated with resposnse to low density lipoprotein subfractions to change in the nature of dietary fat. Atherosclerosis 2000; 149:387-394.

112. Koenig W, Froehlich M, Sund M, Doering A, Fischer H, Loewel H, Hutchinson W, Pepys M. C-reactive protein (CRP) predicts risk of coronary heart disease (CHD) in healthy middle-aged men: results from the MONICA-Augburg cohort study, 1984-85-1992 [abstr]. Circulation 1997; 96(suppl I):I-99.

113. Wu DM, Chu NF, Shen MH, Chang JB. Plasma C-reactive protein levels and their relationship to anthropometric and lipid characteristics among children. J Clin Epidemiol 2003; 56:94-100.

114. Fichtlscherer S, Rosenberger G, Walter DH, Breuer S, Dimmeler S, Zeiher AM. Elevated C-reactive protein levels and impaired endothelial vasoreactivity in patients with coronary artery disease. Circulation 2000; 102:1000-1006.

115. Abramson JL, Weintraub WS, Vaccarino V. Association between pulse pressure and C-reactive protein among apparently healthy US adults. Hypertension 2002; 39:197-202.

Cleland SJ, Sattar N, Petrie JR, Forouhi NG, Elliott HL, Connell JM. Endothelial dysfunction as a possible link between C-reactive protein levels and cardiovascular disease. Clin Sci 2000; 98:531-535.

London GM, Marchias SJ, Guerin AP, Metivier F, Adda H, Pannier B. Inflammation, arteriosclerosis, and cardiovascular therapy in hemodialysis patients. Kidney Int 2003; 84:S88-S93. Preston GA, Barrett CV, Alcorta DA, Hogan SL, Dinwiddle L, Jennette JC, Falk RJ. Serum matrix metalloproteinases MMP-2 and MMP3 levels in dialysis patients vary independently of CRP and IL 6 levels. Nephron 2002; 92:817-823.

Yasmin, McEniery CM, Wallace S, Mackenzie IS, Cockcroft JR, Wilkinson IB. C-reactive protein is associated with arterial stiffness in apparently healthy individuals. Arterioscler Thromb Vasc Biol 2004; 24:969-974.

Brull DJ, Serrano N, Zito F, Jones L, et al. Human CRP gene polymorphism influences CRP levels. Implications for the prediction and pathogenesis of coronary heart disease. Arterioscler Thromb Vasc Biol 2003; 23:2063-2069.

Ridker PM, Rafia N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.

Gabriel AS, Ahnve S, Wretlind B, Martinsson A. Il-6 and IL-1 receptor antagonist in stable angina pectoris and relation of IL-6 to clinical findings in acute myocardial infarction. J Intern Med 2000; 248:61-66.

Humphries SE, Talmud PJ, Hawe E, Bolla M, Day INM, Miller GJ. Apolipprotein E4 and coronary heart disease in middle-aged men who smoke: a prospective study. Lancet 2001; 358:115-119.

Brull DJ, Montgomery J, Sanders J, Dhamrait S, et al. Interleukin-6 gene -174G>C and — 572G>C promoter polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler Thromb Vasc Biol 2001; 21: 1458-1463. Jones KG, Brull DJ, Sian M, Brown LC, et al. Interleukin-6 and the prognosis of abdominal aortic aneurysm. Circulation 2001; 103:2260-2265.

Georges JL, Loukaci V, Poirer O, Evans A, et al. Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction. J Mol Med 2001; 79:300-305. Basso F, Lowe GDO, Rumley A, McMahon AD, et al. Interleukin-6 -174G>C polymorphism and risk of coronary heart disease in West of Scotland Coronary Prevention Study (WOSCOPS). Arterioscler Thromb Vasc Biol 2002; 22:599-604.

Feng D, Tofler GH, Larson MG, et al. Factor VII gene polymorphism, factor VII levels, and prevalent cardiovascular disease: the Framingham Heart Study. Arterioscler Thromb Vasc Biol 2000; 20:593-600.

Girelli D, Russo C, Ferraresi P, et al. Polymorphisms in the factor VII gene and the risk of myocardial infarction in patients with coronary artery disease. New Engl J Med 2000; 343:774-780.

Ridker PM, Hennekens CH, Lindpainter K, Stampfer MJ, et al. Mutation in gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. New Engl J Med 1995; 85:1504-1508.

DeStefano V, Martinelli I, Mannucci PM, et al. The risk of recurrent venous thromboembo-lism among heterozygous carriers of the G202010A proThrombin gene mutation. Br J Haematol 2001; 113:630-635.

Dahlback B. Physiological anticoagulation. Resistance to activated protein protein C and venous thromboembolism. J Clin Invest 1994; 94: 923 -927.

Donahue BS, Gailani D, Higgins MS, et al. Factor V Leiden protects against blood loss and transfusion after cardiac surgery. Circulation 2003; 107:1003-1008. Lindqvist PG, Svensson PJ, Dahlback B, Marsal K. Factor V Q506 mutation (activated protein C resistance) associated with reduced intrapartum blood loss—a possible evolutionary selection mechanism. Thromb Haemost 1998; 79:69-73.

Rey E, Kahn SR, David M, Shrier I. Thrombophilic disorders and fetal loss: a meta-analysis. Lancet 2003; 361:901-908.

136. Lin JH, Lu AYH. Inhibition and induction of cytochrome P450 and the clinical implication. Clin Pharmacokinet 1998; 35:361-391.

137. Relling MV, Cherrie J, Schell MJ, et al. Lower prevalence of the debrisoquin oxidative poor metabolizer phenotype in American black versus white subjects. Clin Pharmacol Ther 1991; 50:308-313.

138. Nakamura K, Goto F, Ray WA, et al. Inter-ethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 1985; 38:402-408.

139. Kagimoto M, Heim M, Kagimoto K, et al. Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. Study of the functional significance on individual mutations by expression of chimeric genes. J Biol Chem 1990; 265:17209-17214.

140. Mahgoub A, Idle JR, Dring LG, et al. Polymorphic hydroxylation of desbrisoquine in man. Lancet 1977; 2:584-586.

141. Johansson I, Lundqvist E, Bertilsson L, et al. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine. Proc Natl Acad Sci USA 1993; 90:11825-11829.

142. http://www.imm.ki.se/CYPalleles.

143. Zhou HH, Wood AJ. Stereoselective disposition of carvedilol is determined by CYP2D6. Clin Pharmacol Ther 1995; 57:518-524.

144. Eichelbaum M, Gross AS. The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects. Pharmacol Ther 1990; 46:377-394.

145. PirMohamed M, Park BK. Cytochrome 450 enzyme polymorphism and adverse drug reactions. Toxicology 2003; 192:23-32.

146. PirMohamed M, Park BK. Genetic susceptibility to adverse drug reactions. Trends Pharmacol Sci 2001; 22:298-305.

147. Maitland-van der Zee AH, de Boer A, Leufkens HGM. The interface between pharmacoepi-demiology and pharmacogenetics. Eur J Pharmacol 2000; 410:13-22.

148. Johnnson JA, Humma A. Pharmacogenetics of cardiovascular drugs. Briefings in Fundamental Genomics and Proteomics 2002; 1:1-14.

149. Tiret L, Rigat B, Visvikis S, et al. Evidence from combined segregation and linkage analysis, that a variant of the angiotensin I converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992; 51:197-205.

150. Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, et al. Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med 1999; 106:544-549.

151. Diegeuz-Lucena JL, Aranda-Lara P, Ruiz-Galdon M, et al. Angiotensin I converting enzyme genotypes and angiotensin II receptors. Response to therapy. Hypertension 1996; 28: 98-103.

152. Stavroulakis GA, Makris TK, Krespi PG, Hatzizacharias AN, et al. Predicting response to chronic antihypertensive treatment with fosinopril: the role of angiotensin-converting enzyme gene polymorphism. Cardiovas Drugs Ther 2000; 14:427-432.

153. Prasad A, Narayanan S, Husain S, et al. Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000; 14:427-432.

154. Schunkert H, Hense HW, Gimenez-Roqueplo AP, Steiber J, et al. The angiotensinogen T235 variant and the use of antihypertensive drugs in a population based cohort. Hypertension 1997; 29:628-633.

155. Van Geel PP, Pinto PP, Voors AA, et al. Angiotensin II type I receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 2000; 35:717-721.

156. Benetos A, Gautier S, Ricard S, et al. Influence of angiotensin-converting enzyme and angiotensin-II type I receptor gene polymorphisms in aortic stiffness in normotensive and hypertensive patients. Circulation 1996; 94:698-703.

Benetos A, Cambien F, Gautier S, et al. Influence of angiotensin II type I receptor gene polymorphism on the effects of perindopril and nitrendipine on arterial stiffness in hypentensive individuals. Hypertension 1996; 28:1081-1084.

Lajemi M, Labat C, Gautier S, Lacolley P, et al. Angiotensin II type 1 receptor -153A/G and 1166A/C gene polymorphisms and increase in aortic stiffness with age in hypertensive subjects. J Hypertens 2001; 19:407-413.

Miller JA, Thai K, Sholey JW. Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999; 56:2173-2180. Tiago AD, Badenhorst D, Skudicky D, Woodiwiss AJ, Candy GP, Brooksbank R, et al. An aldosterone synthase gene variant is associated with improvement in left ventricular fraction in dilated cardiomyopathy. Cardiovasc Res 2002; 54:584-589.

Takahashi T, Yamaguchi E, Furuya K, Kawakami Y. The ACE gene polymorphism and cough threshold for capaicin after cilazapril usage. Respir Med 2001; 95:130-135. Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T. Association of polymorphisms of the renin angiotensin system and bradykinin B2 receptor with angiotensin converting enzyme inhibitor-related cough. J Hum Hypertens 2002; 16:857-863. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359:641-644.

Humma LM, Puckett BJ, Richardson HE, et al. Effect of beta1-adrenoceptor genetic polymorphisms on resting hemodynamics in patients undergoing diagnostic testing for ischaemia. Am J Cardiol 2001; 88:1034-1037.

O'Shaughnessy KM, Fu B, Dickerson C, Thurston D, Brown MJ. The gain-of-function G389R variant of the beta1-adrenoceptor does not influence blood pressure or heart rate response to beta blockade in hypertensive subjects. Clin Sci 2000; 99:233-238. Liggett SB. The pharmacogenetics of ß2 adrenergic receptors: relevance to asthma. J Allergy Clin Immun 2000; 105:487-492.

Liggett SB. Pharmacogenetics of beta-1- and beta-2-adrenergic receptors. Pharmacology 2000; 61:167-173.

LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease a meta-analysis of randomized controlled trials. J Am Med Assoc 1999; 282:2340-2346. Serruys PW, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial. J Am Med Assoc 2002; 287:3215-3222.

Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet 2002; 360:1623-1630. Ichihara K, Satoh K. Disparity between angiographic regression and clinical event rates with hydrophobic statins. Lancet 2002; 359:2195-2198.

Frenette PS. Locking a leucocyte integrin with statins. New Engl J Med 2001; 345:1419-1421.

Marz W, Winkelmann BR. HMG CoA reductase inhibition in the treatment of atherosclerosis: effects beyond lipid lowering. J Kardiol 2002; 9:284-294.

Dela Serna G, Cadarso C. Fenojibrate decreases plasma fibrinogen, improves lipid profile and reduces uricemia. Clin Pharmacol Ther 1999; 66:166-172.

Faggiotto A, Paoletti R. State-of-the-Art lecture. Statins and blockers of the renin-angiotensin system: vascular protection beyond their primary mode of action. Hypertension 1999; 34:987-996.

Ballantyne CM, Herd JA, Stein EA, et al. Apolipopotein E genotypes and response of plasma lipds and progression-regression of coronary atherosclerosis to lipid lowering drug therapy. J Am Coll Cardiol 2000; 36:1572-1578.

Pedro-Botet J, Schaefer EJ, Bakker-Arkema RG, Black DM, et al. Apolipoprotein E genotypes affects plasma lipid response to atorvastatin in a gender specific manner. Atherosclerosis 2001; 158:183-193.

Marques-Vidal P, Bongard V, Ruidavets JB, Fauvel J, et al. Effect of apolipoprotein E alleles and angiotensin converting enzyme insertion/deletion polymorphisms on lipid and lipoprotein markers in middle-aged men and in patients with stable angina pectoris or healed myocardial infarction. Am J Cardiol 2003; 92:1102-1105.

179. Hagberg JM, Wilund KR, Ferrell RE. Apo E gene and gene-environment effects on plasma lipoprotein-lipid levels. Physiol Genomics 2000; 4:101-108.

180. Freeman DJ, Wilson V, McMahon AD, et al. A polymorphism of the cholesteryl ester transfer protein (CETP) gene predicts cardiovascular events in the West of Scotland Coronary Prevention Study (WOSCOPS). Atherosclerosis 2000; 151:91.

181. Carlquist JF, Muhlestein JB, Horne BD, Hart NI, et al. The cholesterol ester transfer protein TaqlB gene polymorphism predicts clinical benefit to statin therapy in patients with significant coronary artery disease. Am Heart J 2003; 146(6):1007-1014.

182. Van Geel PP, Pinto YM, Zwinderman AH, et al. The angiotensin-converting enzyme deletion type gene is associated with ischaemic events and a blunted effect of lipid lowering treatment on angiographically defined coronary atherosclerosis [abstr]. Eur Heart J 1997; IS:1.

183. Bray PF, Cannon CP, Goldschimdt-Clermont P, Moye LA, et al. The platelet PI (AZ) and angiotensin-converting enzymel (PCE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardial 2001; 88:347-352.

184. Martinelli I, Taioli E, Bucciarelli P, et al. Interaction between the G20210A mutation of the proThrombin gene aand oral contraceptive use in deep vein Thrombosis. Arterioscler Thromb Vasc Biol 1999; 19:700-703.

185. Wang JG, Staessen JA. Genetic polymorphisms in the renin-angiotensin system: relevance for susceptibility to cardiovascular disease. Eur J Pharmacol 2000; 410:289-302.

186. Zhu H, Sagnella GA, Dong Y, Miller MA, Onipinla A, Markandu ND, MacGregor GA. Contrasting associations between aldosterone synthase gene polymorphisms and essential hypertension in blacks and in whites. J Hypertens 2003; 21:87-95.

187. Xie HG, Stein CM, Kim RB, Gainer JV, Sofowora G, Dishy V, et al. Human beta2-adrenergic receptor polymorphisms: no association with essential hypertension in black or white Americans. Clin Pharmacol Ther 2000; 67:670-675.

188. Lee JH, Tang MX, Schupf N, Stern Y, Jacobs DM, Tycko B, Mayeux R. Mortality and apolipoprotein E in Hispanic, African-American, and Caucasian elders. Am J Med Genet 2001; 103:121-127.

189. Lamblin N, Bauters C, Hermant X, Lablanche JM, Helbecque N, Amouyel P. Polymorphisms in the promoter regions of MMP-2, MMP3, MMP-9, MMP-12 genes as determinants of anueursymal coronary artery disease. J Am Coll Cardiol 2002; 40:43-48.

190. Humphries SE, Martin S, Cooper J, Miller G. Interaction between smoking and the strome-lysin-1 (MMP3) gene 5A/6A promoter polymorphism and risk of coronary heart disease in healthy men. Ann Hum Genet 2002; 66:343-352.

191. Zhang B, Dhillon S, Geary I, Howell WM, Iannotti F, Day INM, Ye S. Polymorphisms in matrix metalloproteinase-1, 3, 9 and 12 genes in relation to subarachnoid hemorrhage. Stroke 2001; 32:2198-2202.

192. Shimajiri S, Arima N, Tanimoto A, et al. Shortened microsatellite d(CA)21 sequence down-regulates promoter activity of matrix metalloproteinase 9. FEBS 1999; 455:70-74.

193. Peters DG, Kassam A, St Jean PL, et al. Functional polymorphism in the matrix metallopro-teinase-9 promoter as a potential risk factor for intracranial aneurysm. Stroke 1999; 30:2612-2616.

194. Jormsjo S, Ye S, Moritz J, Walter DH, Dimmeler S, Zeiher AM, Henney A, Hamsten A, Eriksson P. Allele-specific regulation of matrix metalloproteinase-12 gene activity is associated with coronary artery luminal dimensions in diabetic patients with manifest coronary artery disease. Circ Res 2000; 86:998-1003.

195. O'Toole L, Stewart M, Padfield P, Channer K. Effect of insertion/deletion polymorphism of the angiotensin-converting enzyme gene on responses to angiotensin-converting enzyme inhibitors in patients with heart failure. J Cardiovasc Pharmacol 1998; 32:988-994.

196. Ohmichi N, Iwai N, Uchida Y, Schichini G, et al. Relationship between the response to the angiotensin converting enzyme (inhibiton) imidapril and the angiotensin converting enzyme genotype. Am J Hypertens 1997; 10:951-955.

197. Perna A, Ruggenenti P, Testa A, et al. ACE genotype and ACE inhibitors induced renopro-tection in chronic proteinuric nephropathies. Kidney Int 2000; 57:274-281.

198. Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. Bradykinin B2 receptor gene polymorphism is associated with angiotensin converting enzyme inhibitor-related cough. Hypertension 2000; 118:1091-1094.

199. Drysdale CM, McGraw DW, Stack CB, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97:483-488.

200. Martinez FD, Graves PE, Baldini M, Solomons S, et al. Association between genetic polymorphisms of the beta 2 adrenoreceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100:3184-3188.

201. Marian AJ, Sofavi F, Ferlic L, Dunn JK, et al. Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary auther-osclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol 2000; 35:89-95.

Dealing With Asthma Naturally

Dealing With Asthma Naturally

Do You Suffer From ASTHMA Chronic asthma is a paralyzing, suffocating and socially isolating condition that can cause anxiety that can trigger even more attacks. Before you know it you are caught in a vicious cycle Put an end to the dependence on inhalers, buying expensive prescription drugs and avoidance of allergenic situations and animals. Get control of your life again and Deal With Asthma Naturally

Get My Free Ebook


Post a comment